Company Quick10K Filing
Monopar Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 9 $-0
10-Q 2019-11-12 Quarter: 2019-09-30
S-1 2019-08-15 Public Filing
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-10 Quarter: 2019-03-31
10-K 2019-02-26 Annual: 2018-12-31
10-Q 2018-11-09 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-11 Quarter: 2018-03-31
10-K 2018-03-26 Annual: 2017-12-31
8-K 2019-06-27 Shareholder Vote
8-K 2018-06-20 Officers
8-K 2018-06-04 Shareholder Vote

Monopar Therapeutics Financials

MONO Metrics, Comps, Filings

Annual | Quarterly

Business

Monopar Therapeutics Inc. (“Monopar” or the ”Company”) is an emerging biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes in cancer patients. Monopar currently has three compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a Phase 3-ready, first-in-class mucoadhesive buccal anti-inflammatory tablet for the prevention and treatment of radiation-induced severe oral mucositis (“SOM”) in oropharyngeal cancer patients; MNPR-201 (GPX-150; 5-imino-13-deoxydoxorubicin), a proprietary Phase 2 clinical-stage topoisomerase II-alpha targeted analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (“uPAR”), for the treatment of advanced solid cancers.

The Company was originally formed in the State of Delaware on December 5, 2014 as a limited liability company (“LLC”) and on December 16, 2015 converted to a C Corporation in a tax-free exchange at which time the Company effected a 1 for 10 reverse stock split. All references to preferred stock and common stock authorized take into account the 1 for 10 reverse stock split. In March 2017, the Company’s Series A Preferred Stock and Series Z Preferred Stock converted into common stock at a conversion rate of 1.2 for 1 and 1 for 1, respectively, which eliminated all shares of Series A Preferred Stock and Series Z Preferred Stock along with a concurrent common stock split of 70 for 1. All references to common stock authorized, issued and outstanding and common stock options take into account the 70 for 1 stock split.

The Company has incurred an accumulated loss of approximately $21.7 million as of December 31, 2018. To date, the Company has primarily funded its operations with the net proceeds from private placements of convertible preferred stock and of common stock and from the cash provided in the MNPR-201 asset purchase transaction. Management believes that currently available resources will provide sufficient funds to enable the Company to meet its minimum obligations through March 2020. The Company’s ability to fund its future operations, including the clinical development of Validive, is dependent primarily upon its ability to execute on its business strategy and obtain additional funding and/or execute collaboration research transactions. There can be no certainty that future financing or collaborative research transactions will occur.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Novelis (NVL) 4% 2.8 4% 9,742,000 8,524,000 12,154,000 511,000 424,000 1,255,000 3,518,000
LED Lighting (LEDL) 0.0 -2,507% 4 12 0 0 -93 -93 -4
Pay My Time (PAYT) 0.0 -136% 108 648 0 0 -147 -147 -0
Ameri Holdings (AMHI) 21% 0.2 -58% 29,478 18,617 42,561 8,774 -17,182 -7,816 -1,601
Morgan Stanley Smith Barney Charter Aspect (MSCD) -6.1 5% 18,285 833 0 0 909 909 -5,554
Owens-Illinois Group (OW) 19% 5.0 4% 10,723,000 6,763,000 1,252,000 396,000 1,188,000 5,894,000
Dominion Minerals (DMNM) 0.0 -7,862% 2 6,912 0 0 -156 -156 -2
Western Uranium (WUC) 13% 1.4 -8% 25,502 3,955 48 6 -2,157 -2,141 -2,954
Luckwel Pharmaceuticals (LWEL) 0.1 -635% 86 1,018 0 0 -543 -543 -72
Noble Vici Group (NVGI) 48% 0.0 -470% 10,687 6,509 12,043 5,785 -50,188 -49,563 -1,395
AEI Income & Growth Fund 25 (AEI25) -6.0 -1% 22,417 623 0 0 -315 559 -3,353
Monopar Therapeutics (MONO) 1.3 -68% 5,595 468 0 0 -3,813 -3,813 -5,130
United Royale (URYL) 0.5 -132% 182 85 0 0 -240 -240 -129
DSwiss (DQWS) 21% 0.2 -180% 232 233 111 24 -417 -391 -84
Solar Quartz Technologies (SQTX) 0.0 -1,337% 92 819 0 0 -1,225 -1,245 -15
Davey Tree Expert (DAVEY) 9% 1.7 6% 570,149 398,166 1,094,814 98,215 32,144 96,951 160,637
US-China Biomedical Technology (UCBB) 0.3 -115% 488 395 0 0 -559 -557 -142
Golden Global (GLDG) 29% 0.0 -750% 684 6,433 95 28 -5,129 -5,129 -0
eWellness Healthcare (EWLL) 0.0 -1,644% 362 5,402 0 0 -5,948 -5,940 -83
Oncor Electric Delivery (C311) 39% 4,495.4 2% 26,283,000 16,237,000 4,147,000 1,610,000 568,000 1,742,000 7,830,993,000

Balance Sheet ($'000)2017-12-312018-12-312019-06-30
Cash80000
Accounts Receivable
Inventory
PP&E
Assets9,9317,3185,595
Accounts Payable
Long-Term Debt
Liabilities312400468
Stockholders' Equity9,6196,9185,127
Income Statement ($'000)2017-12-312018-12-312019-06-30
Revenue00
Cost of Revenue
Gross Profit
R&D9351,774
SG&A1,1661,628
Tax-4-71
Net Income-16,555-3,228
Cash Flow ($'000)2017-12-312018-12-312019-06-30
Cash Operating-2,627-2,887
Cash Investing
Cash Financing9,5360